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Alzheimer’s disease (AD)—the most common type of dementia among the elderly—represents one of the most challenging and
urgent medical mysteries aﬀecting our aging population. Although dominant inherited mutation in genes involved in the amyloid
metabolism can elicit familial AD, the overwhelming majority of AD cases, dubbed sporadic AD, do not display this Mendelian
inheritance pattern. Apolipoprotein E (APOE), the main lipid carrier protein in the central nervous system, is the only gene that
has been robustly and consistently associated with AD risk. The purpose of the current paper is thus to highlight the pleiotropic
roles and the structure-function relationship of APOE to stimulate both the functional characterization and the identiﬁcation of
novel lipid homeostasis-related molecular targets involved in AD.
1.Introduction
Cardiovascular diseases (CVDs), a group of disorders involv-
ing the heart and blood vessels, are currently the world’s
leading cause of death and the top ranking therapeutic
category in terms of prescription drug spending. However,
given the alarming aging of the population and the increase
longevity of humans, Alzheimer’s disease (AD) and other
related dementias are set to become the next great health
crusade of the coming decades [1]. Interestingly, these
progressive degenerative disorders share common etiological
grounds: advancing age, apolipoprotein (apo) E4 inher-
itance, cigarette smoking, high blood pressure, diabetes,
obesity, oxidative stress, and abnormal blood cholesterol
levels all concur to increase one’s liability to develop CVD [2,
3]anddementias[4].Whiletheconnectionbetweenvascular
factors and cognition remains obscure, converging evidence
associates the deﬁciency of APOE with impaired cognition
(see Section 4). Importantly, APOE is the only locus known
to signiﬁcantly contribute to the risk of developing the late-
onset form of AD, with the E4 and E2 alleles, respectively,
increasing and decreasing the risk level [5–7]. Given its
pleiotropic function (see Sections 2 and 3), the mechanisms
by which APOE may exert its eﬀects remain unclear. Yet,
APOE primarily functions as a major lipid transporter in
the periphery and as the main one in the central nervous
system (CNS), putting lipid homeostasis center stage for
the maintenance of cognitive function and the promotion
of AD (see Section 3). Accordingly, alterations in lipid
homeostasis are known to severely impair neuronal function
and elicit progressive disorders such as Farber’s, Gaucher
and Niemann-Pick type C diseases [8–10]. In addition to
its association with AD, APOE genotype also correlates with
a wide range of other dementias and neurodegenerative
disorders (see Section 5). These converging ﬁndings strongly
support the implication of cholesterol/lipid metabolism as a
key factor in neurodegenerative disorder etiology, a concept
still under-studied in the ﬁeld of AD. To stimulate interest
in identifying novel, lipid homeostasis-related molecular
targets involved in AD pathogenesis, this paper reviews
the latest advances and concepts associated with APOE
functions.2 International Journal of Alzheimer’s Disease
2.StructuralOrganizationandToxicological
Properties of the APOE Protein
2.1. Association between APOE and AD: Two Antipode
Isoforms. The APOE gene is mapped onto chromosome 19
and mainly exists in humans as three possible isoforms
diﬀering from each other by single amino acid substitutions
at positions 112 and 158. APOE isoforms are unevenly
distributed in the general population as 77% of people
carry the E3 allele, 15% the E4 allele, and 8% the E2 allele
[5, 11]. Second only to aging, APOE is now recognized as
the most important risk factor for the late-onset form of
AD. Indeed, in addition to numerous case control studies [5,
6, 12] several independent genome-wide association studies
(GWASs) have been performed in homogeneous and hetero-
geneous population of AD and age-matched control cases in
N o r t hA m e r i c a ,E u r o p e ,a n dA s i a[ 13–17]. Using genome-
wide statistical criterion, the APOE4 allele was found to
be associated with AD in all these independent studies.
Accounting for as much as 50% of the genetic variation in
liability to develop AD [18], carriers of the APOE4 allele
who develop AD do so at an earlier age at onset and exhibit
higher levels of soluble beta-amyloid (Aβ) peptide, increased
senile plaque (SP) [19], and neuroﬁbrillary tangle (NFT)
accumulation, as well as more extensive cholinergic deﬁcits
[20–22].
In contrast, the APOE2 variant is associated with a
marked risk reduction of AD [7]. Indeed, carriers of the
APOE2 allele have less AD pathological changes than APOE3
carriers, that is, less pathological Aβ, SP, and NFT levels
[23–26], as well as larger regional cortical thicknesses and
volumes indicative of greater brain reserve against cognitive
decline [27]. These diametrically opposite eﬀects of APOE4
and APOE2, which only diﬀer by subtle amino acid sub-
stitutions at positions 112 and 158, sparked a large interest
in understanding how these proteins diﬀer at the molecular
level.
2.2. APOE Basic Structural Arrangement. APOE is a major
protein constituent of plasma and CNS lipoproteins (see
Box 2.2.1) and functions primarily as a lipid transporter in
thehumanbody.Throughitsbindingtomembersofthelow-
density lipoprotein receptor (LDLR) family present on the
plasma membrane, APOE eﬀectively mediates the uptake of
lipoproteins by cells [28, 29] or activate signalling pathways
that modulate lipid homeostasis [30]. At physiological levels,
a substantial amount of APOE is bound to lipoprotein,
whereas a signiﬁcant fraction of APOE could be associated
with cell surface proteoglycans in a lipid-free state [31]. As
will be discussed in more detail below, these lipid-bound and
lipid-free conformational states likely aﬀect the biological
functions of APOE.
In the lipid-free state, the APOE protein (299 residues)
is organized as two independently folded domains linked
by a protease-sensitive loop (Figure 1): an N-terminal (NT)
domain (residues 1–191) comprised of a four-helix bundle
[32, 33] and a C-terminal (CT) domain (residues 210–299)
whose structural organization has still not been elucidated
despite the crystallization of a proteolytic fragment compris-
ing residues 223–272 [34]. The NT domain was shown to
bear the LDLR binding site [28, 35–37], whereas residues
within the lipid-binding CT domain mediate the lipoprotein
binding [38–40] and the APOE self-association sites [31,
41, 42]( Table 1). Indeed, at physiological concentrations
(micromolar), APOE exists predominantly as a tetramer
[43]. Latest results indicate that, in a lipid-free state, the
CT domain of APOE forms dimer, which then dimerizes
further to form a tetramer [31]. However, APOE is likely
to bind to lipid from its monomeric rather than tetrameric
state. The transition from lipid-free to lipid-bound APOE
may thus involve the formation of multiple intermediate
conformational states [44].
As suggested by the initial discovery that only lipid-
bound APOE binds to LDLR with high aﬃnity [45], the
structural organization of the APOE protein signiﬁcantly
changes when bound to lipids or lipoproteins [44, 46,
47]. Importantly, APOE adopts many lipid-bound con-
formations that depend on lipoprotein size [48], lipid
composition [49] and on the presence of other apolipopro-
teins [50]. Interestingly, recent evidence indicates, however,
that dipalmitoylphosphatidylcholine-(DPPC-) bound APOE
adopts an alpha-helical hairpin conformation in the shape
of a horseshoe, with the CT domain oriented toward the
lipoprotein surface [44, 51, 52]( Figure 1). This hairpin
conformation puts all the known elements of the LDLR
bindingsiteintoastructuralapex,potentiallyexplainingwhy
only lipid-bound APOE binds to LDLR with high aﬃnity
[44, 51].
2.2.1. Box 1
Cholesterol
Phospholipids
Apolipoproteins
Triglycerides
Cholesterol esters
Lipids are hydrophobic molecules that use lipoproteins
to move through aqueous environments. These lipoprotein
particles comprise a nonpolar core of triglycerides (TGs)
and cholesterol esters surrounded by an outer shell of
phospholipids, cholesterol, and apolipoproteins that confer
water solubility on the lipid constituents. In the periphery,
lipoproteins are classiﬁed into four major classes on the basis
of their associated apolipoproteins and their lipid content:
chylomicrons, very-low-density lipoprotein (VLDL), low-
density lipoprotein (LDL), and high-density lipoproteinInternational Journal of Alzheimer’s Disease 3
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Figure 1: Illustration of the lipid-free (a) and DPPC-bound (b) conformational states of APOE isoforms. (a) In a lipid-free state, the NT
and CT domains of APOE interact with each other. (b) The tridimensional conformation of APOE signiﬁcantly changes when bound to
lipid and adopts the shape of a horseshoe, with the CT domain oriented toward the lipoprotein surface. APOE or E: apolipoprotein E; the
red dots line represents salt bridges; C: cysteine; R: arginine; E: glutamate; DPPC: dipalmitoylphosphatidylcholine; NT: N-terminal domain
containing the low-density lipoprotein binding sites; CT: C-terminal domain comprising the lipoprotein binding and APOE self-association
sites.
Table 1: Key structural and functional diﬀerences between the three main human APOE isoforms.
Description E2 E3 E4
Primary sequence
diﬀerence
C112 C112 R112
C158 R158 R158
Structure particularity Disruption of salt bridge network in
the NT domain
Domain interaction (creation of salt
bridges R112-E109 and R61-E255)
LDLR binding <2% normal receptor binding activity High High
Lipoprotein binding HDL HDL VLDL/LDL
Protein stability +++ ++ +
Molten-like-globule
propensity + ++ +++
E: glutamate; C: cysteine; R: arginine; LDLR: low-density lipoprotein receptor; HDL: high-density lipoprotein; VLDL: very-low-density lipoprotein;
+/++/+++, respectively, low/medium/high.
(HDL) [53]. Chylomicrons are rich in APOB and represent
the larger lipoproteins. Their function is that they carry
exogenous (dietary) fatty acids from the intestine to the liver,
skeletal muscles, and adipose tissues. VLDLs are assembled
in the liver with TG, APOC, B, and E and ensure transport
of endogenous lipids from the liver to adipose tissues. Once
in the circulation, VLDLs undergo important TG hydrolysis,
and their apolipoproteins (except APOB) are progressively
eliminated. When cholesterol content becomes greater than
thecontentofTG,VLDLsareconvertedintoLDLwithAPOB
as their main apolipoproteins. LDLs are taken up by the liver
and other tissues through LDL receptor-(LDLR-) mediated
endocytosis. Finally, HDLs are the smallest but the densest
lipoprotein particles because they associate with the highest
proportion of apolipoproteins, mainly APOA-I. Contrary to
the other lipoproteins, HDLs mediate the reverse cholesterol
transport as they extract cholesterol from peripheral tissues
and transport it to the liver for excretion. In the CNS, only
HDL-likelipoproteinscomposedprimarilyofAPOE,APOA-
I, and APOJ are present [54, 55].
2.3. Structural Arrangement and Toxicological Properties of
the APOE Isoforms: Understanding the Antipodes. The APOE4 International Journal of Alzheimer’s Disease
protein is polymorphic, with three common isoforms bear-
ing identical CT domain primary structure, but distinct
NT domain sequence: at positions 112 and 158, E2 has
cysteines, E4 has arginines, and E3 has a cysteine and
an arginine, respectively [32, 56, 57]( Figure 1, Table 1).
These particularities profoundly aﬀect the structural and
functional properties of APOE (reviewed in [44]).
For instance, while APOE3 and APOE4 bind to LDLR
with similar aﬃnities, the APOE2 isoform has less than 2%
of the LDLR binding activity of APOE3, at least in peripheral
cells [58, 59]. This inhibition of the LDLR binding activity is
mediated not only by the arginine-to-cysteine substitution at
position 158, which disrupts the salt bridge network between
residues R92, E96, R103, R150, D151, and D154 [33], but
also by part of the CT domain [59]( Figure 1, Table 1).
Consequently, a double dose of APOE2 is associated with
type III dyslipidemia, a disorder characterized by increased
plasma levels of cholesterol and triglycerides as well as
premature CVD resulting from a defective clearance in
chylomicron remnants [29, 60].
For its part, the cysteine-to-arginine substitution at posi-
tion 112 in the APOE4 NT domain induces the formation of
a salt bridge between arg112 and glu109, modifying the ori-
entationofthesidechainofarg61,whichsubsequentlyforms
a salt bridge with glu255 in the CT domain [39]( Figure 1,
Table 1). This domain interaction apparently inﬂuences the
binding kinetics of lipid-free APOE to lipids, thereby con-
tributing to APOE4 preferences for VLDL and LDL particles,
whereas APOE3 and APOE2 isoforms preferentially bind
HDL particles [38, 39, 50, 61]( Figure 1, Table 1).
As aforementioned, APOE undergoes as extensive con-
formational changes upon binding its ligand (lipid or
lipoprotein), and the transition from lipid-free to lipid-
bound APOE can be facilitated thermodynamically by the
formation of intermediate, partially unfolded APOE con-
formational states [44]. These partially unfolded structures,
also called molten-globule-like conformations,a r eb e l i e v e dt o
be crucial for lipid binding by numerous apos, including
APOE, apoAI [62], and apoAII [63]. Yet, molten-globule-
like conformations are more prone to proteolysis, more vul-
nerable to degradation pathways and have been implicated
in several diseases [44, 64]. Accordingly, the AD-associated
APOE4 isoform possesses the highest propensity to form
molten globule-like conformations, followed by APOE3 and
ﬁnally, APOE2 [65]( Table 1). Conversely, APOE2 possesses
the highest resistance to thermal and chemical denaturation,
followed by APOE3 and APOE4 [66–68]( Table 1). In
accordance with their disparate protein stability, APOE2
is associated with the highest levels of APOE lipoprotein,
whereas APOE4 is associated with the lowest in both the
blood and brain [69–72].
The lower stability of APOE4, its increased susceptibility
for proteolysis as demonstrated by turnover studies in
humans [73] and APOE human knockin mice [74] and its
higher propensity to form molten-globule-like intermediates
that actively bind to phospholipids and membranes could,
in concert with ﬁbrillar Aβ, promote lysosome leakage and
apoptosis through lysosomal membrane disruption [75, 76].
The suboptimal features of APOE4 might also promote neu-
rotoxicity and neuroinﬂammation through the proteolysis
of APOE4 into putative neurotoxic NT and CT fragments,
a process postulated to occur solely in neurons and not in
astrocytes [77]. Furthermore, this proteolytic processing of
APOE is proposed to occur only in the secretory pathway,
and not in the internalization pathway of neurons (i.e., there
is no fragmentation of the astrocyte-derived APOE acquired
by neurons following internalization of APOE-lipoproteins)
[77]. However, synthesis of APOE by neurons remains to be
clariﬁed (see Section 3) through additional studies both, in
model systems and in humans.
In sum, studies on the conformational structure of
APOE have yielded valuable insights into the relationships
that exist between the structure and function of APOE. A
noteworthy ﬁnding from such studies that resulted in our
further understanding of APOE4’s toxicological properties
is that of apoE4’s domain interaction, which promotes the
formation of molten-globule-like conformations. Although
progress has been made toward understanding how the
structural diﬀerences of the three APOE isoforms relate to
phenotype and disease, much work remains to be done.
3. BiologicalFunctionsofAPOEandInteraction
withItsAssociatedPartners
3.1. An Evolutionary Perspective. APOE3 allele appears to
have spread during the later stages of human evolution after
originating from the ancestral APOE4 allele. According to
DNA sequences representing four distinct ethnic groups,
APOE3 is estimated to have spread some 225,000 years ago.
The depth of the tree is estimated at 311,000 years ago (range
0.176–0.579) [78]. Although these sequences analyses do not
inform us of when APOE3 originated as a mutation, they
imply that APOE3 arose before anatomically modern Homo
sapiens ﬁrst migrated from Africa about 100,000 years ago.
Thus, APOE3 was present in Neanderthals (from 300,000
years ago) and in earlier African or European Homo from
which Homo sapiens is thought to have diverged. Only one
APOE genotype has been reported in chimpanzees and other
primatespecies,whichcloselyresembleshumanAPOE4with
arginines at positions homologous to amino acids 112 and
158 (Table 2)[ 79–81]. Many other mammals, including rats,
mice, pigs and cows, also have arginines at these positions
[80].GiventhedepthofhumanAPOEgenealogytreeandthe
similarities between human APOE4 and mammal APOEs,
the APOE4 is considered as the ancestral allele in primates
[79, 80].
3.2. APOE in Cholesterol and Phospholipid Transport. APOE
is the major apolipoprotein in the CNS and plays a central
role in lipid transport in the nervous system [82]. The
dependence of brain cells toward APOE as their chief lipid
carrier and provider is emphasized by the complete absence
of synthesis of other key plasma apolipoprotein such as
apoA1 and apoB in the CNS [83]. In the brain, APOE is
p r o d u c e dm a i n l yb ya s t r o c y t e s[ 83–86] and to a lesser extent
by microglia [87]. Initial studies investigating the site of
APOEproductioninthebrainsuggestedthatonlyastrocytes,International Journal of Alzheimer’s Disease 5
Table 2: APOE polymorphisms in humans and species diﬀerences.
ApoE residue
(+signal peptide)
Population prevalence
(%)
112
(130)
158
(176)
Human
APOE2 8 C C
APOE3 77 C R
APOE4 15 R R
Chimp 100 R R
Gorilla 100 R R
Orangutan 100 R R
Mice 100 R R
Rats 100 R R
APOE: apolipoprotein E; C: cysteine; R: arginine.
oligodendrocytes, and ependymal cells synthesized APOE
[86, 88]. Under diverse physiological and pathological con-
ditions, neurons have also been reported to express APOE,
albeit at a much lower level than astrocytes, in humans [89],
neuronal cell lines [90–92], mice [93], and APOE transgenic
mice [94]. Surprisingly, a signiﬁcant number of studies
failed to observe the synthesis of APOE in neurons both in
rodent and human brains [20, 86, 95–99]. Clearly, additional
studies are needed to clarify the issue of APOE synthesis
within neurons, especially since numerous studies found
no evidence of APOE mRNA expression within neurons
[86, 95, 100, 101].
CholesterolhomeostasisintheCNSisregulatedindepen-
dently from the periphery due to the presence of the blood-
brain barrier (BBB) which prevents the plasma cholesterol
from crossing into the CNS [102]. Maintenance of the
cholesterol pool in the brain is based on the regulation of
three important steps: synthesis, transport (recycling), and
excretion [103]. The ﬁrst step, synthesis, is provided by
de novo anabolism that converts acetyl-CoA to cholesterol
through a series of 20 complex reactions in which 3-
hydroxy-3-methylglutaryl coenzyme A reductase (HMGCR)
is the rate limiting enzyme [104, 105]. While neurons of
the mature brain can synthesize cholesterol, they mainly
rely on astrocytes to meet their cholesterol requirements
for neuronal maintenance, growth, repair and dendritic
reorganization [102, 106, 107].
Recycling of lipids reﬂects an energy-eﬃcient system
when compared to the biosynthesis of cholesterol because
the latter involves a complex pathway requiring over 20
reactions [103, 107, 108]. Cholesterol homeostasis is main-
tainedthroughaseriesofinterdependentpathwaysincluding
that of cholesterol transport in which APOE is of central
signiﬁcance. APOE is the primary apolipoprotein in the
CNS followed by APOJ (also known as Clusterin) [109],
which has also been identiﬁed as a genetic risk factor in
AD by genome-wide association approaches [17, 106, 110].
In the brain, APOE is produced and secreted by astrocytes
and microglia and is subsequently lipidated by the ATP-
bindingcassettetransporterA1(ABCA1)toformlipoprotein
particles (Figure 2)[ 71, 102] .T h er o l eo fA B C A 1i st o
regulate the eﬄux of cholesterol and phospholipids from the
cell onto HDL in plasma [111]. It has been proposed that
ABCA1 catalyses the initial transfer of cholesterol onto lipid-
poor APOE and that ATP-binding cassette transporter G1
(ABCG1) ﬁnalizes the full lipidation of the apolipoprotein
(Figure 2)[ 112, 113]. Although many lines of evidence
support a role of ABCG1 in the regulation of cholesterol
eﬄux, its function remains elusive. Tangier disease provides
supporting evidence for the central role of ABCA1 in
cholesterolhomeostasisasthisdiseaseiscausedbymutations
in the ABCA1 gene and is characterized by HDL deﬁciency
and cholesterol accumulation in macrophages and hepato-
cytes [114, 115]. Consistent with this phenomenon, ABCA1
mouse knockouts exhibit poorly lipidated APOE which in
turn has been shown to inﬂuence Aβ metabolism [111, 116].
The pivotal role of ABCA1 in cholesterol homeostasis makes
it of potent interest as a target for AD treatment.
Following lipidation, the APOE-HDL-like lipoparticles
are endocytosed by speciﬁc members of the LDLR family
(including LDLR, LDLR-related protein (LRP), APOER2,
and the VLDLR) present on both neuronal and nonneuronal
cells (Figure 2)[ 102, 117]. APOE endocytosis provides
cholesterol to the neuron that can subsequently be used
for synthesis of plasma membranes, synaptogenesis, and
dendritic proliferation [118]. The functions of APOJ in lipid
homeostasis and Aβ metabolism are very similar to those
of APOE in that they are both carriers of cholesterol in
the CNS and they both modulate amyloid ﬁbrillogenesis
and clearance [109, 119, 120]. Albeit their similar functions,
APOE and APOJ are present on diﬀerent HDL-like lipopro-
tein particles which diﬀer in composition: APOJ-lipoprotein
particles are lipid poor and have a higher phospholipid-to-
cholesterol ratio compared to APOE-lipoprotein particles
[85, 119, 121]. As well, there is some debate as to whether
the cholesterol transport pathway used by APOE and APOJ
diﬀers since the receptor for APOJ, megalin/LRP-2, is not
expressed by neurons and APOJ levels which are signiﬁcantly
increased in AD brain [122, 123] are unaltered in ABCA1
knockout mice suggesting that APOJ does not use ABCA1
for lipidation [111, 119, 124].
Excess cholesterol cannot be degraded in the brain due
to its sterol ring. The predominant pathway to excrete
cholesterol from the CNS is therefore to convert it into a
more lipophilic 24(S)-hydroxycholesterol which can cross
the BBB [112, 125]. This metabolite, only produced in
neurons, is then directed to the liver where it can be excreted
in the form of bile acids [126]. Other pathways account
for about 36% of the excretion; however, the mechanisms
remain unclear and controversial [125, 127].
APOE variants continue to receive great attention today
and account for more genetic variance (25%) in cholesterol
metabolism than any other gene [128]. APOE4/4 versus
APOE3/3 carriers have 3 to 15% higher LDL and total
cholesterol, depending on the population, diet, and exercise.
APOE alleles show marked eﬀects on blood lipids during
dietary shifts. For example, in humans on a low-fat baseline
diet, adding 300 mg cholesterol/day (2 egg yolks) caused
serumtotalcholesteroltoincreasefourfoldmoreinAPOE4/46 International Journal of Alzheimer’s Disease
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Figure 2: Cholesterol transport in the CNS. APOE is synthesized by astrocytes and assembles free cholesterol (FC) and phospholipids (PLs)
to form HDL-like particles. (1) Lipidation of these lipoparticles is facilitated via the mobilization and distribution of lipids to the cell surface
by ABCA1/G1. Once secreted in the extracellular space, these HDL-like particles are directed either toward the circulation through the BBB
and/or to neurons requiring lipids. (2) These APOE-HDL-like particles are recognized and endocytosed by members of the cell surface
LDLR family (LDLR, LRP, APOER2, VLDLR), and (3) the FC is released within neurons and can be used for neurite elongation and/or
synaptogenesis (4). As a result of lipid internalization, the endogenous synthesis of cholesterol within neurons (via the HMGCR pathway)
is repressed (5). Excess cholesterol will be removed from neurons through its conversion into 24S-hydroxycholesterol (24S-OH) which is
mediated by cholesterol 24S-hydroxylase (CYP46) (6). This sterol can now freely cross lipophilic membranes of the BBB and exit the brain
for elimination (7). APOE or E: apolipoprotein E; BBB: blood-brain barrier; RER: rough endoplasmic reticulum; HMGCR: 3-hydroxy-3-
methylglutaryl coenzyme A reductase; HDL: high-density lipoprotein; LDLR: low-density lipoprotein receptor.
carriers than in APOE3/3 and even greater relative increases
of LDL cholesterol [129]. As aforementioned, APOE4
preferentially binds triglyceride-rich lipoproteins (LDL and
VLDL), whereas APOE3 binds preferentially to HDL [38, 39,
50, 61]. These diﬀerences in lipoprotein binding by APOE3
and APOE4 greatly inﬂuence lipoprotein clearance and the
LDL/HDL ratios, which are risk factors in cardiovascular
diseases. APOE4 has smaller eﬀects on the risk of cardiovas-
cular disease than on AD, in the range of 10% to 50%, with
eﬀects peaking during middle age [130]. In contrast, APOE4
is the most common AD risk factor throughout the world,
with a 10- to 20-fold higher risk in Caucasian homozygous
E4 carriers. The impact of the APOE4 variant varies widely
across diﬀerent populations/ethnicities, which can likely be
explained, at least partly, by an interaction between genetic
andenvironmentalfactors.Forexample,YorubansinNigeria
showed 70% less dementia than African Americans [131], an
incidence diﬀerence which may be related to their lifelong
low-fat diet.
3.3. APOE-Mediated Beta Amyloid Transport. Because the
possible roles of APOE in amyloid metabolism have been
extensively reviewed recently by Kim and colleagues [106],
only the potential role of APOE lipoproteins as scavengers
of soluble beta amyloid (Aβ) peptides will be discussed in
this section [21]. Indeed, evidence suggests that APOE binds
avidly to soluble nonaggregated Aβ fragments [6, 132]. As it
was demonstrated in rat primary neuronal cell cultures, the
APOE lipoproteins containing Aβ may then be internalized
via the APOE receptor internalization pathway [133, 134].
Following internalization, these Aβ fragments could be
released and degraded via the endosomal/lysosomal pathway
[20, 21]. The observation that Aβ reaches high intracellular
concentration without aﬀecting neuronal survival strength-
ens the proposed compartmentalization of internalized Aβ
in endosomes/lysosomes [133, 134]. Interestingly, APOE
binding aﬃnity for Aβ was shown to follow an E2 > E3 >
E4 gradient [135]. This provides an additional mechanism
explaining,atleastinpart,themarkeddiscrepancythatexists
between the APOE2/E4 variants and the risk to develop AD.
Indeed, the protective APOE2 variant binds Aβ more avidly
than the deleterious APOE4 variant and might therefore be
more eﬃcient than its APOE4 counterpart at clearing Aβ
fragments from the extracellular space [21].International Journal of Alzheimer’s Disease 7
3.4.APOEandNeuroinﬂammation. Inadditiontomediating
the endocytosis of cholesterol and phospholipids into neu-
rons,APOEhavebeenassociatedwithantioxidantproperties
in both in vitro and in vivo models [136, 137]. Additionally,
in the periphery, APOE- and APOB-enriched lipoproteins
are known to transport vitamin E and other lipid soluble
antioxidant species [138]. Irrespective of APOE genotype,
a plethora of oxidative reaction products has been found
increased in the brains of AD and mild cognitive impairment
subjects [139–141]. However, markers of oxidative damage
are more intense in individuals who carry one or two copies
of the APOE4 allele [137, 142].
As in many neurodegenerative diseases including Parkin-
son’s disease [143], neuroinﬂammation caused by an abnor-
mal activation of astrocytes and microglia is featured promi-
nently as a pathological characteristic of AD [144–146]. This
neuroinﬂammatory response is primarily driven locally by
neuronal cell loss and extracellular Aβ deposits evidenced
bythecolocalizationofnumerousinﬂammation-relatedpro-
teins (i.e., cytokines, complement receptors and acute-phase
proteins), activated microglia clusters, and amyloid plaques
[147, 148]. In vitro studies aﬃrm that Aβ peptides can
trigger an inﬂammatory response as measured by increases
in standard neuroinﬂammatory proteins (i.e., cytokines
and nitric oxide synthase) as well as nitric oxide release
[149]. Neuroinﬂammation, especially when prolonged, is of
concern for AD due to the accumulation of inﬂammatory
molecules that are proven toxic to neurons resulting in
neuronal dysfunction or death [146, 150].
As previously discussed, APOE is involved in numerous
pathways inﬂuencing AD onset and progression, including
Aβ production, clearance, and degradation as well as its
role in cholesterol homeostasis. Since the initial ﬁnding
of decreased inﬂammation from glial Aβ-induced APOE
production [145, 151], numerous studies have reported
that APOE has an anti-inﬂammatory function and that
its stimulation by Aβ acts as a negative feedback sys-
tem [145, 151, 152]. In support of this, APOE-deﬁcient
mice have a greater neuroinﬂammatory response relative
to control mice [145]. In vitro studies also conﬁrm that
exogenously administered human APOE has the ability to
attenuate Aβ-induced astrocyte activation as measured by a
decrease in cyclo-oxygenase 2 (COX2) and inducible nitric
oxide synthase [153]l e v e l s[ 145, 151]. However, the anti-
inﬂammatory eﬀect of APOE is reversed in the absence of an
Aβ-inducedinﬂammatoryresponseasassessedbyexpression
of interleukin-1b, a proinﬂammatory cytokine, following
exogenously administered APOE [151]. Taken together these
ﬁndings suggest a dual role for APOE in which it attenuates
Aβ-induced neuroinﬂammation but also overproduction of
APOE by this same activated glia can lead to an exacerbation
oftheinﬂammation[151,154].Althoughthemechanismsby
which APOE inﬂuences the inﬂammatory response remain
elusive, the primary candidate is the modulation of nuclear
factor kappa-light-chain-enhancer of activated B cells (NF-
κB) transcription and signalling pathway [147, 155, 156].
AlsoinvestigatediswhethertheroleofAPOEinneuroin-
ﬂammation is aﬀected in an isoform-speciﬁc manner. In vivo
studies using human APOE knockin mice have shown that
following lipopolysaccharide (LPS) administration, APOE4
mice have a greater neuroinﬂammatory response relative
to the APOE3 mice, suggesting that APOE4 has a less
eﬀective anti-inﬂammatory eﬀect [157]. In addition to the
decreasedanti-inﬂammatoryfunctionofAPOE4,cellculture
studies investigating the proinﬂammatory function of APOE
in the absence of Aβ have demonstrated that astrocytes
and microglia show a greater inﬂammatory response when
exogenous APOE4 is added compared with the APOE3
isoform [151].
Collectively, these ﬁndings imply that APOE4 has a
reduced anti-inﬂammatory eﬀect as well as a more vigorous
proinﬂammatory function. Although these results infer an
isoform-speciﬁc immunomodulatory eﬀect, the eﬃciency of
APOE2 requires further investigation.
Neuroinﬂammation is a prominent characteristic of AD;
however, it remains uncertain whether it is promoting
AD progression or merely a byproduct of the disease
[148]. Numerous studies have investigated the eﬀects of
nonsteroidal anti-inﬂammatory drugs (NSAIDs) on AD risk
and treatment [158–161]. While they remain controversial, a
trendtowardadecreaseinADriskisobservedinpopulation-
based studies with long-term use of NSAIDs, suggesting
an early role of inﬂammation in AD [160, 162]. Recently,
the NSAID risk reduction beneﬁts have been shown to be
restricted to the apoE4 carrier subgroup in the population-
based Cardiovascular Health Cognition Study [163], further
highlighting the interactions linking apoE metabolism to the
immune system.
4. The Neurophysiological andFunctional
Correlatesof the APOE4 Aging Brain
4.1. Overview of APOE Functions. Acting as the main choles-
terol transporter of the CNS [83], APOE plays a determinant
role in neuronal maintenance, growth, repair, and reorgani-
zation [164, 165]. While CNS neurons produce just enough
cholesterol to survive and grow ineﬃcient synapses [166],
a glia-derived factor consisting of cholesterol complexed to
APOE-containing lipoproteins strongly promotes synapse
formation [107, 167]. Indeed, the formation of multiple,
highly eﬃcient synapses in the developing CNS and in the
injured adult brain was shown to be highly dependent on
additional cholesterol supplies provided by the glial system
[107]. It is therefore understood that the plastic properties of
the brain through terminal remodeling and synaptogenesis
are highly dependent on CNS cholesterol bioavailability.
Needless to say that ineﬀective cholesterol transport asso-
ciated with APOE deﬁciencies or deﬁciency in one of its
most important receptors, the LDL receptor (LDLR), should
invariably alter plasticity-dependent cognitive reﬁnement
and synaptic remodeling.
4.2. APOE-Deﬁcient Mouse: A Model of Impaired Cogni-
tion. Consistent with the human APOE4/AD observations
indicating the APOE levels are tightly regulated by its
polymorphisms, APOE-deﬁcient mice which express no
APOE in the brain display: (a) progressive age-related8 International Journal of Alzheimer’s Disease
memory loss [168–174], (b) progressive loss of cortical
and hippocampal synapses that reaches nearly 70% by 18
months of age [170, 173, 175], (c) a marked reduction
of cholinergic activity [176], (d) impaired injury-mediated
synaptic remodeling [171], (e) impaired reinnervation pro-
cesses [177, 178], and (f) deterioration of phospholipids
metabolism during maturation [179]. Moreover, APOE
deﬁciency also potentiates the detrimental eﬀects of oxida-
tive stress on learning/memory through the expression of
inﬂammatory proteins in the cerebral vasculature [180].
Takentogether,theseAPOE-deﬁcientmousemodelﬁndings,
whether through oxidative stress, altered cholinergic system
function, or compromised synaptic plasticity mechanisms,
all corroborate the particular susceptibility of the hippocam-
pus to APOE deﬁciency in mice. Strikingly, this increased
vulnerability of hippocampus-related functions to APOE
deﬁciency is consistent with disproportionate hippocampal
volume atrophy in the early stages of AD [181], particularly
so in carriers of the APOE4 allele [182, 183].
Similarly, in absence of LDLR, the main receptor
for APOE, synaptic remodelling, and plasticity is gravely
impaired in LDLR knockout (KO) mice [184]. These mice
exhibit progressive age-related memory loss and signiﬁcant
synaptic loss in the CA1 area (−35% at 11 months) of
the hippocampus [184]. Interestingly, adult LDLR KO mice
expressing no brain LDLR have a 50% reduction in APOE
synthesis relative to wild-type mice [185] ,af e a t u r en o t
that dissimilar from the ﬁnding that APOE4/4 AD subjects
express only 50% of the normal brain APOE levels of
APOE3/3 individuals [72, 186]. Relative to wild-type mice,
basal hippocampal Aβ1-42 are found to be signiﬁcantly
higher in both the LDLR KO and dual APOE/LDLR KO
mice, corroborating the potential role of APOE lipoproteins
as scavengers of soluble Aβ peptides (see Section 3). Fur-
thermore, the fact that the APOE4 allele and LDLR genetic
variations synergistically enhance the risk of developing
AD by 11-fold [187] highlights the importance of both
APOE synthesis and internalization in AD. Interestingly, it
was shown a few years ago that cultured astrocytes from
APOE4 and APOE3 human knock-in mice synthesize and
release APOE to the same extent [188]. This suggests that
the reported lower levels of brain APOE protein associated
with the APOE4 allele might also be mediated by the
internalization of APOE within brain cells. Whether the
recycling and/or degradation of the APOE4–LDLR complex
is diﬀerentially regulated when compared to its APOE3
counterpart warrants further studies.
Interestingly, the introduction of human APOE3 or
APOE4 in the APOE KO mice completely prevents the
cognitive deﬁcit typical of these APOE-deﬁcient mice [189,
190]. However, it should be noted that human APOE4
expression in targeted replacement mice leads over time
to (a) a marked reduction of APOE levels in the brain
[191], (b) compromised synaptic plasticity [192], and (c),
defective cognitive performance as well as impaired long-
term potentiation (LTP) [190, 193, 194]. More interestingly,
cross-breeding of the humanized APOE4 or APOE3 mice
with APP717 amyloid overexpressing transgenic mice almost
completely prevented the characteristic accumulation of Aβ
deposits reported in hippocampal and cortical areas [195].
These ﬁndings are entirely consistent with the proposed
notion that brain APOE acts as a local active scavenger of
extracellular Aβ [132, 134].
4.3. APOE4 and Impaired Cognition in Nondemented Indi-
viduals. In humans, APOE4 is known to increase the risk
of both familial and sporadic AD [5, 6] and to precipitate
conversion to AD among mild-cognitive impairment (MCI)
patients [196, 197]. MCI refers to a condition in which
memory or, less commonly, another cognitive function is
below normal but does not interfere with daily functioning.
MCI is considered a transitional state between normal for-
getfulness and AD. Moreover, converging evidence indicates
that, over time, APOE4 increases the likelihood of cognitive
impairments in clinically normal 50+ years old individuals
[198]. Indeed, APOE4 carriers under the age of 60 years
exhibited greater acceleration of age-related memory decline
relative to noncarriers, despite ongoing normal clinical
status [199]. This memory decline occurring prior to MCI
diagnosis was previously found to be relatively speciﬁc as no
diﬀerences were found in the domains of language, spatial
skills, or executive function [200].
Among dominant views on what underlies this APOE4
and AD association, one is based on the observation
that APOE4 proteins are the least eﬀective in facilitating
the metabolism of pathogenic Aβ forms, which indirectly
augments Aβ burden [201]. Alternatively, another potent
explanation for this increased risk of AD in APOE4 carriers
is the deleterious eﬀects of reduced protein expression
on cholesterol homeostasis. Indeed, the APOE4 gene was
shown to encode signiﬁcantly less APOE proteins than
E3/E2 counterparts, thereby providing insuﬃcient levels of
functional APOE4 to maintain CNS cholesterol homeostasis
and neuronal health [134, 191, 193]. This notion ﬁnds
compelling support in the neuroprotective properties of
the APOE2 allele against late-life development of sporadic
AD [24], as this APOE polymorphism is associated with
a tenfold increase in APOE protein levels compared to
both APOE3 and APOE4 [193]. Equally important is the
demonstration that treatment of hypercholesterolemia with
HMGCR inhibitors (statins), a family of lipids-lowering
agents [27], in middle-aged individuals confers neuropro-
tection against late-life development of sporadic AD [202–
204]. Furthermore, treatment by statins resulted in selective
improvement of AD-prone hippocampal and frontal-related
cognitive functions in APOE4 carriers, but without aﬀecting
CSF Aβ42 or total tau levels [205]. Further studies are
clearly needed to assess the impact of diﬀerent statin therapy
regimens on histopathological hallmarks of AD-like Aβ
metabolism and tau deposition.
4.4. APOE4 Eﬀects on Hippocampal/Entorhinal Cortex Imag-
ing and Volume Measurements. Alongside the association
between APOE4 and cognitive alterations mostly in the
sphere of memory among nondemented individuals, neu-
roimagingstudieshaveprovidedsigniﬁcantstructuralaswell
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in APOE4 carriers. While structural neuroimaging studies
have yielded mixed results over the past decade, recent
years have witnessed signiﬁcant advances in our ability to
image structural atrophy using techniques such as diﬀu-
sion tensor imaging (DTI) and voxel-based morphometry
(VBM). A VBM study that compared gray matter density
between cognitively intact APOE4/E3 carriers and APOE3
homozygotes of all ages (age 19 to 80) showed reduced
gray matter density in carriers of the APOE4 allele in right
medial temporal and bilateral frontotemporal regions [206].
Another study demonstrated that the presence of an APOE4
allele in non-demented older adults was also associated
with decreases in cognition joint with white/gray matter
changes in the medial temporal cortex using VBM and DTI
[207]. A similar VBM study more recently demonstrated
that late-onset AD patients displayed a selective pattern of
parahippocampal white matter loss, while early-onset AD
patients experienced a more widespread pattern of posterior
white matter atrophy. Among both AD groups, APOE4
positivity was associated with a greater parahippocampal
white matter loss, supporting the contention that the APOE4
eﬀect is restricted to parahippocampal white matter regions
a n dn o tr e l a t e dt oa g eo fo n s e t[ 208]. In MCI patients,
left hippocampus grey matter atrophy was found to exert a
stronger eﬀect than the right hippocampus or bilateral basal
forebrain in the prediction of amnestic MCI occurrence, and
this left hippocampal atrophy was accentuated in APOE4
carriers relative to noncarriers [209]. This hippocampus-
speciﬁc pattern of cerebral atrophy was also found in mild
AD APOE4 carriers as opposed to APOE4 noncarriers who
tended to exhibit greater frontoparietal atrophy [210]. In
parallel, an emerging AD Neuroimaging Initiative (ADNI)
study showed that APOE4 positive amnestic MCI patients
with more brain atrophy were at greatest risk of functional
degradation [211], highlighting the value of genetic and vol-
umetric MRI information as predictors of disease conversion
to AD.
Recent extensions to these volumetric studies described
the implication of the APOE gene on brain atrophy in
relation with AD cerebrospinal ﬂuid (CSF) biomarkers
levels at diﬀerent disease stages. This emerging line of
research ﬁnds compelling support in the recent ADNI-
deriveddemonstrationthattheAPOEgenereachedgenome-
wide signiﬁcance for association with CSF levels of both
Aβ (1–42) and tau [212]. Interestingly, another ADNI
study looking to deﬁne the genetic backgrounds to normal
cognition, MCI (AD disease stages), and AD in relation to
CSF levels found lower CSF Aβ (1–42) levels with APOE4
gene dose in each disease stage. Moreover, AD patients who
were APOE4 homozygotes exhibited elevated total-tau (t-
tau) and phosphorylated-tau (p-tau) 181 levels [213]. This
is consistent with previous ﬁndings of a signiﬁcant age
∗ APOE4 genotype interaction for p-tau231, isoprostane,
and t-tau CSF concentrations increased with age [214]. In
keeping with this notion, cognitively intact older adults
with reduced CSF Aβ (1–42) levels were more likely to be
APOE4 positive (48% versus 11% in high Aβ (1–42) levels
older adults), to exhibit increased whole brain loss, increased
ventricular expansion, and faster hippocampal atrophy rates
[215]. Similarly, APOE4-related decreased CSF Aβ (1–
42) and increased tau concentrations were associated with
signiﬁcantly higher rates of brain tissue loss that were both
regional as well as disease stage speciﬁc [216]. Conversely,
APOE2 carriers had slower rates of hippocampal atrophy
concomitant with decreased preclinical AD pathology (i.e.,
higher CSF levels of Aβ (1–42), lower CSF p-tau and t-
tau concentrations) [217]. It therefore seems that along
with genetics and volumetric MRI, CSF biomarkers of
AD provide valuable quantitative measurements for early
detection/disease progression across disease stages.
Functional neuroimaging ﬁndings in APOE4 carriers
have also abounded in the last decade. A recent study
conducted with non-demented older adults found an asso-
ciation between APOE4 and decline in regional cerebral
blood ﬂow (rCBF) over time in brain regions especially
susceptible to pathological changes in AD [218]. Accelerated
rates of decline in brain functions of APOE4 carriers were
suggested to contribute to an increased risk of AD and a
younger age at onset [218]. These ﬁndings are based on
a previous experiment conducted with a group of healthy
elderly subjects among whom APOE4 carriers exhibited
signiﬁcantly diﬀerent patterns of brain activation during a
nonverbal memory task. Interestingly, these diﬀerences in
brain activation were not thought to reﬂect task diﬃculty,
but were rather interpreted as memory-related alterations
of cognitive processing that may result from subclinical
incipient AD pathology and/or APOE-related neurophys-
iologic heterogeneity [219]. Other evidence suggests that
baseline metabolic reductions in the entorhinal cortex (EC)
accurately predicted the conversion from normal aging to
MCI. At follow-up, those who declined showed memory
impairment and hypometabolism in temporal lobe neocor-
tex and hippocampus particularly in APOE4 carriers [198].
These convergent cognitive and neuroanatomic ﬁndings
support the notion that APOE genotype modulates the
clinical phenotype of AD through inﬂuence on selective
brain networks [210] and highlights the inﬂuence of genetic
variance on imaging, cognitive measures, and risk for AD.
In sum, ﬁndings on the role of APOE on cognition
have converged to highlight its manifest involvement in AD-
prone memory and learning functions. Indeed, these APOE-
related cognitive alterations were found to be concomitant
with reduced cerebral metabolism, impoverished neuronal
interconnections as well as damaged cerebral vasculature
particularlyexacerbated in medial temporal brain structures.
Owing to substantial technical advances made over recent
years, prevention of AD could greatly beneﬁt from our
acquired ability to relate genetic variances with abnormal
brain neurophysiology patterns in cognitively intact individ-
uals.
5. APOE and Other Neurodegenerative Diseases
5.1. Other Dementias. Next to AD, one of the leading causes
of neurodegenerative dementia is Lewy body dementia
(LBD).Asitsnameclearlypoints on,thecentralpathological
hallmark is the cortical Lewy bodies, as opposed to the10 International Journal of Alzheimer’s Disease
classical Lewy bodies described in Parkinson’s disease [143],
whichareintracytoplasmic(ubiquitin-positive)aggregatesof
α-synuclein that accumulates in the substancia nigra. While
they contain less NFT, the majority of LBD brains contain
as much SP as in AD brains [220]. Moreover, APOE4 is
consistently found associated with LBD [221–223].
Frontotemporal dementia (FTD) represents a heteroge-
neous group of neurodegenerative disorders characterized
pathologically by frontal and/or temporal lobes atrophy
and their tau isoforms pattern. Indeed, while speciﬁc FTD
tauopathies typically result from the pathological aggre-
gation and phosphorylation of one or two tau protein
isoforms, all 6 tau isoforms are hyperphosphorylated in AD
(for a review of FTDs classiﬁcation see [224]). The best
knownFTD-associateddiseasesthatwillbereviewedherefor
their associations with APOE are Pick’s disease, corticobasal
degeneration (CBD), and progressive supranuclear palsy
(PSP).
Pick’s disease (PiD) is characterized by ballooned neu-
rons named Pick cells that are swollen due to the presence of
cytoplasmicinclusionscontainingtauproteins(Pickbodies).
APOE associations with PiD risk or age at onset are not
consistently found [225, 226]. Of note, Farrer et al. reported
that the APOE4 frequency is higher in PiD than in controls
(but lower than in AD) and that the number of APOE4
allele copies is inversely proportional to the age at onset
[227]. Consistent with results from Singleton et al. study
in LBD [223], Gustafson et al. also found that the APOE4
allele frequency was higher in PiD than in controls, but with
APOE4/4 and APOE2 frequencies being, respectively, lower
and higher than those reported for AD [228].
The next two FTDs, CBD and PSP, are also referred to
as Parkinson-plus diseases due to parkinsonism symptoms.
Diﬀerential diagnostic between AD, CBD, PSP, and PD
is clinically diﬃcult. However, CBD and PSP pathologies
manifest themselves in tau-positive astroglial and neuronal
inclusions. CBD and PSP diﬀer both by the form of their
tau inclusions—namely, “doughnut-shaped” in CBD as
opposed to “tuft-shaped” in PSP—and by their intracerebral
distribution [229]. Two studies illustrate particularly well the
controversy about APOE4 association with CBD. On one
hand, Pickering-Brown et al. did not ﬁnd any association
between APOE4 and clinical expression of CBD [226]. On
the other hand, Schneider et al. reported a higher APOE4
allele frequency in 11 CBD cases [230]. To date, evidence of
an association between PSP and APOE genotype is scarce,
mostly due to small sample size [226, 231–235]. However, a
higher frequency of the APOE2 allele (but not the APOE4
allele) in PSP relative to controls was found in a Japanese
population [236].
Parkinson’s disease, 2nd age-related neurodegenerative
disorder in importance after AD and 1st extrapyramidal
disorder,isalsoassociatedwithdementia.Parkinson’sdisease
dementia (PDD) accounts for 0.2 to 0.5% of dementia cases
in the general population over the age of 65 and aﬀects
24% to 31% of PD patients [237]. The risk of dementia is
4 to 6 times higher in PD patients than in controls [238].
More than one-third of PD patients meet criteria for AD and
the diﬀerential diagnostic between PDD with and without
AD is diﬃcult [239, 240]. These results conducted to the
rise of associations studies between APOE polymorphism
and PD. However, these studies have yielded mixed results.
While APOE polymorphism was not associated with PD in
several studies [143, 241–248], others did ﬁnd associations
but diﬀered in the terms of this association. Indeed, lower
E4 allele frequency and higher E4 allele frequency were,
respectively, associated in sporadic and familial PD with
cognitive decline [249]. Dementia in PD was repetitively
associated with the E4 allele [250–253] and also with the E2
allele [254]. Age at onset appeared to be modulated by APOE
genotype (earlier onset E4 > E3 > E2) [251, 252, 255, 256]
and by sex [257]. Moreover, two meta-analyses sought to
further corroborate the association between APOE and the
riskofPDanddementiainPD.Theﬁrstone[258]conﬁrmed
previous results indicating that APOE2, which is protective
in AD, increases the risk of PD [254, 259]. The more
recent one [260] acknowledged that APOE4 is signiﬁcantly
associated with an increased risk of dementia in PD but the
authorswarnthatpublicationbiasandheterogeneoussource
of data could have confounded this result.
As regard to Huntington’s disease [261], another well-
known neurodegenerative extrapyramidal movement disor-
der with neuronal intranuclear inclusion and late dementia,
the APOE4 allele has been associated with a later age at
onset [262], whereas the E2 and E3 alleles appear to require
other factors in order to modulate age at onset [263, 264].
Finally, multiple system atrophy [265], a rare Parkinson-plus
extrapyramidal disorder characterized mostly by brainstem
glialLewybody-likeinclusionsandsubsidiarytauinclusions,
hasnotbeenassociatedwithanyAPOEallele[231,232,266].
5.2. Other Neurodegenerative Disorders. Amyotrophic lateral
sclerosis (ALS), the most common motor neuron disease,
also presents α-synuclein-positive inclusions, and, notably,
5% of patients will develop an FTD [267]. The association
betweenAPOEandALSriskiscontroversial[268–272].Most
striking results are the association with age at onset, with
the APOE4 and APOE2 alleles, respectively, decreasing [270,
272] and increasing the age [270, 273], as well as the ﬁnding
that APOE plasma levels (but not APOE genotype) were
correlated with a faster rate of deterioration and shortened
survival time [274]. Multiple sclerosis (MS) has also been
tested for its association with APOE genotype given the
importance of inﬂammation for the disease process and
the aﬄiction of the myelin, which is vulnerable to lipid
deﬁciency. There is a relative agreement on the negative
eﬀectof theAPOE4alleleondisease severityand progression
rate [275–279], but a single cross-sectional study showed
that homozygosis for this allele increases both the risk for
and the rate of progression of MS [280]. Contradictory
results to these reported ﬁndings have also been published
[241, 265, 278, 281–284].
The last neurodegenerative disease investigated in this
paper section is age-related macular degeneration (ARMD).
ARMD is the leading cause of vision loss in the elderly
in developed countries. ARMD is associated with druse,
an extracellular deposit primarily composed of activatedInternational Journal of Alzheimer’s Disease 11
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complement components, Aβ peptide, APOE, and ubiquitin.
It is noteworthy that the molecular composition of the
drusen is highly similar to that of the SP found in AD.
Interestingly, AD and ARMD also share some cardiovascular
risk factors. These evidence prompted association studies
between APOE genotype and ARMD. Two associations were
reproductively observed: the APOE4 allele is less frequent
among ARMD patients [285] and reduces the risk of
developing the disease by up to 40%, whereas the APOE2
allele is more frequent and increases the risk by up to
20% [286]. Kov´ acs et al. stressed the opposite frequencies
between APOE4/APOE2 and ARMD/AD and highlighted the
rare occurrence of ARMD among AD patients [287]. As for
Baird et al., they pointed that APOE is the most consistently
associated gene with ARMD. They showed that APOE4 is
protective against ARMD and/or increases its age at onset,
whereas APOE2 decreases the age at onset of ARMD [288].
Interestingly,Maleketal.presentedamousemodelofARMD
in which aged human APOE transgenic mice were fed a
high-fatcholesterol-richdiet[289].Theyfoundthatthemice
displayed APOE isoform-dependent pathologies of diﬀerent
severity. Mice expressing the human APOE4 were the most
severelyaﬀectedones;theydevelopedchangesthatmimicked
ARMD pathology, but that could not be attributed solely to
age or high-fat cholesterol-rich factors.
In sum, neurodegenerative diseases, with or without
dementia, encompass a large spectrum of disorders. The
more we learn about these pathologies, the more similarities
and diﬀerences are found, which result in a constant
reclassiﬁcation of these diseases. One common pathological
hallmark is the deposition of misfolded protein (amyloid-β,
tau, α-synuclein, etc.). Through the modulation of disease
risk, age at onset, and/or rate of progression, APOE is
involved in an isoform-dependent manner in all the diseases
reviewed here (Table 3). With the noticeable exception of
ARMD, the APOE4 allele is predominantly deleterious,
whereas the APOE2 is beneﬁcial. This evidence suggests that
APOEpolymorphismconfersarisksusceptibilitynotspeciﬁc
to AD, but to neurodegenerative disease in general.
6. Conclusion
We have reviewed the postulated roles of APOE4 in the
development of diﬀerent forms of dementia and particularly,
in sporadic AD. While age remains a key determinant
that modulates the onset and expression of AD pathology,
g e n e t i cr i s kf a c t o r ss u c ha sA P O E 4a p p e a rt op l a yac e n t r a l
role in the pathophysiology of this disease, years, if not
decades, before clinical diagnosis. The combined use of
genetic proﬁling and gene targeting will allow scientists
to better target the biochemical mechanisms regulating
the loss of synapses and the accumulation of amyloid
deposits in the aging and diseased brain. The discovery that
compounds such as estrogens, probucol, indomethacin, and
even rosiglitazone can signiﬁcantly induce APOE synthesis
andsecretionbothinvitroandinvivo,andenhancecognitive
performances [290–294] in small clinical trials certainly
suggested a potential therapeutic role for APOE modulators
in AD. The surprising convergence of these biochemical,
pharmacogenomic, and clinical observations raises exciting
new possibilities and certainly interesting new therapeutic
avenues for the treatment and prevention of a genetically-
deﬁned, sizeable subset of Alzheimer’s disease subjects.
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